{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:17:46Z","timestamp":1764937066896,"version":"build-2065373602"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81270582","81470290"],"award-info":[{"award-number":["81270582","81470290"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.bcmd.2019.03.010","type":"journal-article","created":{"date-parts":[[2019,3,31]],"date-time":"2019-03-31T09:35:55Z","timestamp":1554024955000},"page":"88-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged \u226560\u202fyears and has lower toxicities: Comparison with low-dose chemotherapy"],"prefix":"10.1016","volume":"77","author":[{"given":"Li","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanling","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weilai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liya","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingwan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingnong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juying","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinjun","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyan","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2019.03.010_bb0005","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/ajh.24253","article-title":"Myelodysplastic syndromes: contemporary review and how we treat","volume":"91","author":"Gangat","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2019.03.010_bb0010","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/asheducation-2006.1.199","article-title":"Hematopathological concepts and controversies in the diagnosis and classification of myelodysplastic syndromes","author":"Vardiman","year":"2006","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0015","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.mayocp.2015.04.001","article-title":"Myelodysplastic syndromes: diagnosis and treatment","volume":"90","author":"Steensma","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.bcmd.2019.03.010_bb0020","doi-asserted-by":"crossref","first-page":"60","DOI":"10.6004\/jnccn.2017.0007","article-title":"Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Greenberg","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw.: JNCCN"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0025","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2013-03-492884","article-title":"Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet","volume":"122","author":"Malcovati","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0030","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/cncr.22508","article-title":"Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0035","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/1097-0142(20011015)92:8<1999::AID-CNCR1538>3.0.CO;2-B","article-title":"High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens","volume":"92","author":"Beran","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0040","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.22779","article-title":"Intensive chemotherapy is not recommended for patients aged >60\u202fyears who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes","volume":"110","author":"Knipp","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0045","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.leukres.2016.07.005","article-title":"Effect of granulocyte colony-stimulating factor priming combined with low-dose cytarabine and homoharringtonine in higher risk myelodysplastic syndrome patients","volume":"48","author":"Wang","year":"2016","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bcmd.2019.03.010_bb0050","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s00432-011-1020-2","article-title":"Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS","volume":"137","author":"Wu","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2019.03.010_bb0055","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1080\/10428190903096719","article-title":"Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome","volume":"50","author":"Wu","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0060","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1532\/IJH97.A10424","volume":"82","author":"Li","year":"2005","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.bcmd.2019.03.010_bb0065","first-page":"238","volume":"71","author":"Saito","year":"2000","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.bcmd.2019.03.010_bb0070","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.3109\/10428194.2015.1096351","article-title":"Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study","volume":"57","author":"Wu","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0075","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00277-015-2547-0","article-title":"Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group","volume":"95","author":"Lubbert","year":"2016","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bcmd.2019.03.010_bb0080","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1007\/s12325-015-0263-8","article-title":"Decitabine for treatment of myelodysplastic syndromes in Chinese patients: an open-label, phase-3b study","volume":"32","author":"Wu","year":"2015","journal-title":"Adv. Ther."},{"key":"10.1016\/j.bcmd.2019.03.010_bb0085","doi-asserted-by":"crossref","first-page":"44985","DOI":"10.18632\/oncotarget.6242","article-title":"A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome","volume":"6","author":"Jeong","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0090","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1111\/j.1349-7006.2012.02386.x","article-title":"Phase I\/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan","volume":"103","author":"Oki","year":"2012","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bcmd.2019.03.010_bb0095","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3324\/haematol.2011.046078","article-title":"A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome","volume":"96","author":"Lee","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0100","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.3109\/10428194.2010.524324","article-title":"Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian\/South Korean multi-institutional clinical experience","volume":"51","author":"Iastrebner","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0105","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1200\/JCO.2008.19.6550","article-title":"Multicenter study of decitabine administered daily for 5\u202fdays every 4\u202fweeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial","volume":"27","author":"Steensma","year":"2009","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2019.03.010_bb0110","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2006-05-021162","article-title":"Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0115","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/cncr.22376","article-title":"Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0120","doi-asserted-by":"crossref","first-page":"e95473","DOI":"10.1371\/journal.pone.0095473","article-title":"Decitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysis","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0125","doi-asserted-by":"crossref","first-page":"5495","DOI":"10.1158\/0008-5472.CAN-05-2385","article-title":"DNA methylation changes after 5-aza-2\u2032-deoxycytidine therapy in patients with leukemia","volume":"66","author":"Yang","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcmd.2019.03.010_bb0130","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2003-03-0687","article-title":"Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2\u2032-deoxycytidine (decitabine) in hematopoietic malignancies","volume":"103","author":"Issa","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0135","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0140","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0145","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin. Radiat. Oncol."},{"key":"10.1016\/j.bcmd.2019.03.010_bb0150","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.7314\/APJCP.2014.15.3.1247","article-title":"Molecular evaluation of DNMT3A and IDH1\/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype Indian acute myeloid leukemia patients","volume":"15","author":"Ahmad","year":"2014","journal-title":"Asian Pac. J. Cancer Prev.: APJCP"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0155","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2019.03.010_bb0160","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/gcc.21960","article-title":"Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms","volume":"51","author":"Brecqueville","year":"2012","journal-title":"Gene Chromosome Cancer"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0165","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1182\/blood-2011-08-373159","article-title":"Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness","volume":"118","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0170","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ajh.23373","article-title":"Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance","volume":"88","author":"Patnaik","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2019.03.010_bb0175","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00432-010-0947-z","article-title":"Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia","volume":"137","author":"Gu","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2019.03.010_bb0180","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.leukres.2013.09.006","article-title":"Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine","volume":"37","author":"Li","year":"2013","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bcmd.2019.03.010_bb0185","first-page":"349","article-title":"Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2\u2032-deoxycytidine","volume":"114","author":"Lubbert","year":"2001","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2019.03.010_bb0190","doi-asserted-by":"crossref","first-page":"6627","DOI":"10.7314\/APJCP.2015.16.15.6627","article-title":"Decitabine in the treatment of acute myeloid leukemia and myelodysplastic syndromes, which combined with complex karyotype respectively","volume":"16","author":"Gao","year":"2015","journal-title":"Asian Pac. J. Cancer Prev.: APJCP"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0195","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0200","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","article-title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts","volume":"126","author":"Malcovati","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0205","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2011-09-377994","article-title":"SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value","volume":"119","author":"Patnaik","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0210","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2019.03.010_bb0215","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/ng.1031","article-title":"Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes","volume":"44","author":"Graubert","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcmd.2019.03.010_bb0220","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/leu.2010.52","article-title":"Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS\/myeloproliferative neoplasms","volume":"24","author":"Kosmider","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0225","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/ng.2696","article-title":"Somatic SETBP1 mutations in myeloid malignancies","volume":"45","author":"Makishima","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcmd.2019.03.010_bb0230","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/leu.2010.98","article-title":"Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q)","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0235","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1182\/blood-2011-12-399337","article-title":"Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes","volume":"119","author":"Thol","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0240","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/leu.2011.44","article-title":"Recurrent DNMT3A mutations in patients with myelodysplastic syndromes","volume":"25","author":"Walter","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0245","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/leu.2011.71","article-title":"Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias","volume":"25","author":"Itzykson","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2019.03.010_bb0250","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","article-title":"TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979619300646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979619300646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:34:49Z","timestamp":1761050089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979619300646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":50,"alternative-id":["S1079979619300646"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2019.03.010","relation":{},"ISSN":["1079-9796"],"issn-type":[{"type":"print","value":"1079-9796"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged \u226560\u202fyears and has lower toxicities: Comparison with low-dose chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2019.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}